Headlines about Regulus Therapeutics (NASDAQ:RGLS) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regulus Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.6431588287157 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Regulus Therapeutics (NASDAQ RGLS) opened at $1.23 on Friday. The company has a market capitalization of $127.86, a price-to-earnings ratio of -0.91 and a beta of 1.55. Regulus Therapeutics has a 12-month low of $0.79 and a 12-month high of $2.60. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77.
RGLS has been the subject of several research reports. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Saturday, September 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th. Finally, Leerink Swann initiated coverage on Regulus Therapeutics in a research report on Friday, January 5th. They issued an “outperform” rating and a $2.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. Regulus Therapeutics has a consensus rating of “Hold” and a consensus price target of $2.46.
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
What are top analysts saying about Regulus Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regulus Therapeutics and related companies.